Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
Crinetics Pharmaceuticals (NASDAQ: CRNX) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the financial performance and provide a business update.
Participants can join via phone using domestic (1-833-470-1428) or international (1-404-975-4839) dial-in numbers with Conference ID: CRNXQ1. Alternatively, they can access the live webcast through the Events section of Crinetics' website. Participants are advised to connect 15 minutes before the call starts to ensure timely access. The webcast recording will be available later in the Investor Relations section of www.crinetics.com.
Crinetics Pharmaceuticals (NASDAQ: CRNX) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per giovedì 8 maggio 2025, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30 ET per discutere le performance finanziarie e fornire un aggiornamento aziendale.
I partecipanti possono unirsi tramite telefono utilizzando i numeri di accesso nazionali (1-833-470-1428) o internazionali (1-404-975-4839) con ID Conferenza: CRNXQ1. In alternativa, possono accedere al webcast dal settore Eventi del sito web di Crinetics. Si consiglia ai partecipanti di connettersi 15 minuti prima dell'inizio della chiamata per garantire un accesso tempestivo. La registrazione del webcast sarà disponibile successivamente nella sezione Relazioni con gli Investitori di www.crinetics.com.
Crinetics Pharmaceuticals (NASDAQ: CRNX) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el jueves 8 de mayo de 2025, después del cierre del mercado. La compañía llevará a cabo una llamada de conferencia y un webcast a las 4:30 p.m. ET para discutir el rendimiento financiero y proporcionar una actualización empresarial.
Los participantes pueden unirse por teléfono utilizando los números de marcado nacionales (1-833-470-1428) o internacionales (1-404-975-4839) con ID de Conferencia: CRNXQ1. Alternativamente, pueden acceder al webcast en la sección de Eventos del sitio web de Crinetics. Se aconseja a los participantes que se conecten 15 minutos antes de que comience la llamada para asegurar un acceso oportuno. La grabación del webcast estará disponible más tarde en la sección de Relaciones con Inversores de www.crinetics.com.
크리네틱스 제약 (NASDAQ: CRNX)는 2025년 1분기 재무 결과 발표를 2025년 5월 8일 목요일, 시장 종료 후로 예정했습니다. 회사는 오후 4시 30분 ET에 재무 성과를 논의하고 사업 업데이트를 제공하기 위해 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
참가자는 국내 전화번호(1-833-470-1428) 또는 국제 전화번호(1-404-975-4839)를 사용하여 회의 ID: CRNXQ1로 전화로 참여할 수 있습니다. 또는 크리네틱스 웹사이트의 이벤트 섹션을 통해 실시간 웹캐스트에 접근할 수 있습니다. 참가자는 통화 시작 15분 전에 연결하여 적시에 접속할 수 있도록 하는 것이 좋습니다. 웹캐스트 녹화본은 www.crinetics.com의 투자자 관계 섹션에서 나중에 제공될 예정입니다.
Crinetics Pharmaceuticals (NASDAQ: CRNX) a prévu l'annonce de ses résultats financiers du premier trimestre 2025 pour le jeudi 8 mai 2025, après la fermeture du marché. L'entreprise organisera une conférence téléphonique et un webinaire à 16h30 ET pour discuter des performances financières et fournir une mise à jour de l'entreprise.
Les participants peuvent se joindre par téléphone en utilisant les numéros d'appel nationaux (1-833-470-1428) ou internationaux (1-404-975-4839) avec l'ID de conférence : CRNXQ1. Alternativement, ils peuvent accéder au webinaire en direct via la section Événements du site Web de Crinetics. Les participants sont invités à se connecter 15 minutes avant le début de l'appel pour garantir un accès rapide. L'enregistrement du webinaire sera disponible plus tard dans la section Relations Investisseurs de www.crinetics.com.
Crinetics Pharmaceuticals (NASDAQ: CRNX) hat die Bekanntgabe seiner finanziellen Ergebnisse für das erste Quartal 2025 für Donnerstag, den 8. Mai 2025, nach Börsenschluss angesetzt. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die finanzielle Leistung zu erörtern und ein Unternehmensupdate zu geben.
Teilnehmer können sich telefonisch über die nationalen (1-833-470-1428) oder internationalen (1-404-975-4839) Einwahlnummern mit der Konferenz-ID: CRNXQ1 einwählen. Alternativ können sie über den Bereich Veranstaltungen auf der Website von Crinetics auf den Live-Webcast zugreifen. Es wird empfohlen, dass die Teilnehmer sich 15 Minuten vor Beginn des Anrufs einwählen, um einen rechtzeitigen Zugang zu gewährleisten. Die Aufzeichnung des Webcasts wird später im Bereich Investor Relations auf www.crinetics.com verfügbar sein.
- None.
- None.
SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Conference Call & Webcast
Thursday, May 8 @ 4:30 p.m. ET
| Domestic: | 1-833-470-1428 |
| International: | 1-404-975-4839 |
| Conference ID: | CRNXQ1 |
Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.
The webcast will be archived on the Investor Relations section of www.crinetics.com.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
When will Crinetics Pharmaceuticals (CRNX) release Q1 2025 earnings?
How can investors join the CRNX Q1 2025 earnings call?
What time is the Crinetics (CRNX) Q1 2025 earnings conference call?
Where can I find the replay of CRNX's Q1 2025 earnings call?
